IQE PLC

Declaration of Voting Results & Voting Rights Announcements • Aug 1, 2022

National Storage Mechanism | Additional information

RNS Number : 1405U

IQE PLC

01 August 2022

IQE plc

Total Voting Rights

Cardiff, UK

1 August 2022

("IQE" or the "Company")

Total Voting Rights

As at 31 July 2022, the Company's issued share capital consisted of 804,638,414 ordinary shares of 1 pence each ("Ordinary Shares"). The Company holds 4,115 Ordinary Shares in treasury. Therefore the total number Ordinary Shares with voting rights in the Company is 804,634,299.

Shareholders may use this figure (804,634,299) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Contacts:

IQE plc

+44 (0) 29 2083 9400

Amy Barlow

Peel Hunt LLP (Nomad and Broker)

+44 (0) 20 7418 8900

Edward Knight

Paul Gillam

James Smith

Headland Consultancy (Financial PR)

+ 44 (0) 20 38054822

Andy Rivett-Carnac: +44 (0) 7968 997 365

ABOUT IQE

http://iqep.com

IQE is the leading global supplier of advanced compound semiconductor wafers and materials solutions that enable a diverse range of applications across:

·    handset devices

·    global telecoms infrastructure

·    connected devices

·    3D Sensing

As a scaled global epitaxy wafer manufacturer, IQE is uniquely positioned in this market which has high barriers to entry. IQE supplies the whole market and is agnostic to the winners and losers at chip and OEM level. By leveraging the Group's intellectual property portfolio including know-how and patents, it produces epitaxy wafers of superior quality, yield and unit economics.

IQE is headquartered in Cardiff UK, with c. 685 employees across nine manufacturing locations in the UK, US, Taiwan and Singapore, and is listed on the AIM Stock Exchange in London.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRXVLFLLDLZBBK